Determining patient's coagulation profile, ie detecting a bleeding tendency or the opposite, a
thrombotic risk, is crucial for clinicians in many situations. Routine coagulation assays and …

Maintaining normal hemostasis relies on a regulated system of procoagulant and
anticoagulant pathways, and disruption of these processes leads to the loss of hemostatic …

Emicizumab, a bispecific monoclonal antibody, bridges activated factor IX (FIXa) and FX,
replacing the function of missing FVIIIa to restore effective hemostasis in persons with …

Real‐world data on emicizumab use and monitoring in paediatric severe haemophilia A
(HA) patients are scarce. We therefore sought to evaluate safety, efficacy, and laboratory …

Background Emicizumab is a bispecific antibody that bridges factor IXa and factor X to
restore hemostasis in patients with hemophilia A (HA). Its efficacy and safety have been …

Introduction The formation of neutralizing antifactor VIII (fVIII) antibodies, called inhibitors, is
the most common complication in modern haemophilia A care. Novel non‐factor …

Hemophilia A (HA) is an X-linked hereditary bleeding disorder caused by deficiency of
coagulation factor (F) VIII activity. One of the greatest complications in the treatment of HA is …

Introduction Real‐world data on prophylaxis of severe haemophilia A (HA) patients treated
by emicizumab are scarce. Aim To study the efficacy and safety of longitudinal emicizumab …

Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies
between assays for the various sorts of FVIII molecules. The advent of novel nonfactor …

The advent of extended half‐life (EHL) recombinant clotting factors and innovative non‐
factor replacement therapeutics, such as emicizumab, offers several advantages over …